You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Early Disease Considerations in Triple Negative Breast Cancer

  • Authors: Sara A. Hurvitz, MD; Jonathan W. Malara, PharmD, BCOP; Jennifer Litton, MD; Massimo Cristofanilli, MD, FACP; Denise Yardley, MD
  • CME / ABIM MOC / CE Released: 12/1/2022
  • Valid for credit through: 12/1/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Nurses - 1.00 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, pathologists, surgeons, nurse practitioners (NPs), physician assistants (PAs), pharmacists, and nurses.

The goal of this activity is that learners will be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data associated with the impact of ctDNA in early-stage triple negative breast cancer
  • Have greater competence related to
    • Selecting the appropriate systemic therapy for patients with early-stage triple negative breast cancer
    • Mitigating adverse events that present for patients receiving therapy for early-stage triple negative breast cancer 
  • Demonstrate greater confidence in their ability to
    • Incorporate the latest advances in management into early-stage triple negative breast cancer care


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Sara A. Hurvitz, MD

    Professor​
    Director, Breast Cancer Clinical Trials Program​
    David Geffen School of Medicine​
    University of California Los Angeles​
    Medical Director​
    Jonsson Comprehensive Cancer Center Clinical Research Unit​
    Los Angeles, California

    Disclosures

    Sara A. Hurvitz, MD, has the following relevant financial relationships:
    Contracted researcher for: Ambrx; Amgen; Arvinas; AstraZeneca; Bayer; Cytomx; Daiichi Sankyo; Dignitana; Genentech; Gilead; GlaxoSmithKline; Immunomedica; Lilly; Macrogenics; Novartis; Pfizer; OBI Pharma; Orinove; Phoenix Molecular Designs, Ltd.; Pieris; PUMA Biotechnology; Radius; Roche; Sanofi; Seagen, Inc.; Zymeworks

  • Jonathan W. Malara, PharmD, BCOP

    Clinical Pharmacy Specialist
    Breast Medical Oncology
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Jonathan W. Malara, PharmD, BCOP, has no relevant financial relationships.

  • Jennifer Litton, MD

    Professor
    Vice President Clinical Research
    Department of Breast Medical Oncology
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Jennifer Litton, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Ayala; Medivation; Pfizer
    Research funding from: AstraZeneca; EMD Serono; Genentech (former); GlaxoSmithKline (former); Medimmune (former); Merck; Novartis (former); Pfizer; Zenith

  • Massimo Cristofanilli, MD, FACP

    Professor of Medicine
    Director of Breast Medical Oncology
    Weill Cornell Medicine
    New York, New York

    Disclosures

    Massimo Cristofanilli, MD, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Celcuity; Ellipses; Lilly; Menarini; Olaris
    Speaker or member of speakers bureau for: Foundation Medicine; Guardant; Pfizer
    Research funding from: Lilly; Pfizer

  • Denise Yardley, MD

    Sarah Cannon Senior Investigator
    Breast Cancer Research Program
    Principal Investigator
    Nashville, Tennessee

    Disclosures

    Denise Yardley, MD, has no relevant financial relationships.

Editor

  • John Churchwell, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    John Churchwell, PhD, has the following relevant financial relationships:
    Formerly employed by an ineligible company: Medtronic (ended 2021)

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-22-393-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Early Disease Considerations in Triple Negative Breast Cancer

Authors: Sara A. Hurvitz, MD; Jonathan W. Malara, PharmD, BCOP; Jennifer Litton, MD; Massimo Cristofanilli, MD, FACP; Denise Yardley, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/1/2022

Valid for credit through: 12/1/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Updates on Systemic Therapy in Triple Negative Breast Cancer: Neoadjuvant/Adjuvant Therapies​

Increase your clinical acumen for systemic therapies and toxicity management in triple negative breast cancer.
Jennifer Litton, MD; Jonathan W. Malara, PharmD, BCOP

Circulating Tumor DNA (ctDNA) and Minimal Residual Disease in Triple Negative Breast Cancer​

Hear the latest about ctDNA and molecular progression vs clinical progression in triple negative breast cancer.
Massimo Cristofanilli, MD, FACP; Denise Yardley, MD
 

Educational Impact Challenge

The goal of this activity is that learners will be better able to understand the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print